

Curriculum Vitae

James K. Cunningham

Education:	DEGREE	YEAR	FIELD OF STUDY
The Claremont Graduate School	PhD	1985	Social Psychology
The Claremont Graduate School	MA	1980	Social Psychology
California State University, Northridge	BA	1978	Social Psychology

Employment:

2006-	Department of Family and Community Medicine, College of Medicine, The University of Arizona, Tucson, Arizona
1995-2005	Public Statistics Institute, Irvine, California
1990-1995	Office of Policy and Planning, Orange County Health Care Agency, Santa Ana, California
1984-1990	Research Services and Administration, House Ear Institute, Los Angeles, California

Honors/Awards:

Canada-Mexico Joint Award in North American Studies
Fulbright U.S. Scholar Program

Harry F. Scoville Practitioner Research Award
Western Governmental Research Association

Achievements in Alcohol and Drug Research
California Association of Alcohol and Drug Administration

Service/Outreach

Regional/State

2006-2010	Arizona Governor's Substance Abuse Epidemiology Work Group
2008-2012	Advisory Work Group Member: U.S. Counties along the Mexico Border Initiative, Substance Abuse and Mental Health Services Administration

National

2006-2013	National Institute on Drug Abuse (NIDA) Community Epidemiology Work Group
-----------	---

Chapters in Scholarly Books and Monographs:

1. **Cunningham J. K.** (2012) Illicit-Drug Trends in Phoenix and Arizona: 2012. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2012*. Bethesda, MD: National Institute on Drug Abuse. (in press)
2. **Cunningham J. K.** (2011) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2011*. Bethesda, MD: National Institute on Drug Abuse.
3. **Cunningham J. K.** (2010) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2010*. Bethesda, MD: National Institute on Drug Abuse.
4. **Cunningham J. K.** (2009) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2009*. Bethesda, MD: National Institute on Drug Abuse.
5. **Cunningham J. K.** (2008) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2008*. Bethesda, MD: National Institute on Drug Abuse.
6. **Cunningham J. K.** (2007) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2007*. Bethesda, MD: National Institute on Drug Abuse.
7. **Cunningham J. K.** (2006) Hospital admissions data: Access and uses in drug analysis. In *Assessing Drug Abuse Within and Across Communities*. Bethesda, MD: National Institute on Drug Abuse.
8. Dode I. L. **Cunningham J. K.** (2006) Drug abuse trends in Phoenix and Arizona. In *Epidemiologic Trends in Drug Abuse. Volume II. Proceedings of the Community Epidemiology Work Group—2006*. Bethesda, MD: National Institute on Drug Abuse.
9. **Cunningham J. K.** (2006) Methamphetamine, cocaine, and heroin/opioid hospital admissions in Arizona—1990-2004. In *Epidemiologic Trends in Drug Abuse. Volume I. Proceedings of the Community Epidemiology Work Group--2006*. Bethesda, MD: National Institute on Drug Abuse.
10. **Cunningham J. K.**, Thielemeyer M. A. (2001) *Sexual Risk Behavior and HIV Treatment Optimism: HIV-Positive Persons at Ryan White CARE Act Providers in Orange County*. Santa Ana, CA: County of Orange Health Care Agency.
11. **Cunningham J. K.**, Thielemeyer M. A. (1998) *Amphetamine-Related Hospital Admissions: Trends and Regional Variation in California (1987-1996)*. Irvine, CA: Public Statistics Institute.
12. **Cunningham J. K.** (1998) *Child Health and Disability Program (CHDP) in Orange County: Client Demographics and Services Provided (8/96-7/97)*. Irvine, CA: Public Statistics Institute.

13. **Cunningham J. K.**, Thielemeir M. A., Stalcup S. A., Stalcup J. A. (1997) *Heroin/Opioid-Related Hospital Admissions: Trends and Regional Variations in California (1986-1995)*. Irvine, CA: Public Statistics Institute.
14. **Cunningham J. K.**, Thielemeir M. A. (1996) *Amphetamine-Related Emergency Admissions: Trends and Regional Variations in California (1985-1994)*. Irvine, CA: Public Statistics Institute.
15. **Cunningham J. K.** (1996) *Epidemiologic Trends of HIV/AIDS in Orange County*. Santa Ana, CA: County of Orange Health Care Agency.
16. **Cunningham J. K.**, Thielemeir M. A., Hicks D. A. (1996) *Cocaine-Related Emergency Admissions: Trends and Regional Variations in California (1985-1994)*. Irvine, CA: Public Statistics Institute.
17. **Cunningham J. K.**, Thielemeir M. A. (1995) *Amphetamine-Related Emergency Admissions: Trends and Regional Variations in California (1984-1993)*. Irvine, CA: Public Statistics Institute.
18. **Cunningham J. K.**, Nafday A. (1995) *Trends in Alcohol and Other Drug-Related Admissions: Orange County Acute Care Hospitals (1983-1992)*. Santa Ana, CA: County of Orange Health Care Agency.
19. **Cunningham J. K.**, Serpe R. T., Robinson G. J., Nereson C. (1994) *Alcohol Use, Smoking and Obesity in Orange County: General Population, Whites, Latinos, and Vietnamese*. Santa Ana, CA: County of Orange Health Care Agency.
20. **Cunningham J. K.** (1994) *Accuracy of Cocaine-Related Emergency Room Data in California*. Santa Ana, CA: County of Orange Health Care Agency.
21. **Cunningham J. K.** (1993) *Risk Indicator Monitoring System (RIMS): History, Objectives and Technical Framework*. Santa Ana, CA: County of Orange Health Care Agency.
22. **Cunningham J. K.**, Serpe R. T., Robinson G. J. (1992) *Homeless Persons in Orange County: Demographics, Needs and Health-Risk Behaviors*. Santa Ana, CA: County of Orange Health Care Agency.
23. **Cunningham J. K.** (1992) *Risk Indicator Monitoring System (RIMS): Initial Measures and Findings on Alcohol and Other Drugs in Orange County*. Santa Ana, CA: County of Orange Health Care Agency.
24. **Cunningham J. K.** (1991) Drug monitoring systems and drug epidemiology at the local level. In Mecca A. (ed.) *Community Works Summit*. Sacramento, CA: California Health and Welfare Agency.
25. **Cunningham J. K.**, Stoeckert J. A. (1988) Improvements in cochlear implant appearance: The user's view. *Hearing Instruments*. 39: 32, 34, 82.
26. Berliner K. I., **Cunningham J. K.** (1987) Tinnitus suppression in cochlear implantation. In Hazell J. W. P. (ed.) *Tinnitus*. London: Churchill Livingstone.

Refereed Journal Articles:

27. **Cunningham, J.K.**, Liu, L.-M., Callaghan, R. (2013) Essential (“precursor”) chemical control for heroin: impact of acetic anhydride regulation on US heroin availability. *Drug and Alcohol Dependence*. (in press)
28. Callaghan, R. C., Sanches, M., Gatley, J. M., **Cunningham J. K.** (2013) Assessing the impacts of the minimum legal drinking age on alcohol-related health-service utilization in hospital settings in Ontario, Canada: a regression-discontinuity approach. *American Journal of Public Health*. (in press)
29. **Cunningham J. K.**, Maxwell, J. C., Campollo, O., Liu, L. M., Lattyak, W. J., Callaghan R. C. (2013) Mexico’s precursor chemical controls: Emergence of less potent types of methamphetamine in the United States. *Drug and Alcohol Dependence*. 129: 125-136.
30. **Cunningham J. K.**, Callaghan R. C., Tong D., Liu L.-M., Li H.-Y., Lattyak W. J. (2012) Changing over-the-counter ephedrine and pseudoephedrine products to prescription only: Impacts on methamphetamine clandestine laboratory seizures. *Drug and Alcohol Dependence*. 126: 55-64.
31. Callaghan R. C., **Cunningham J. K.**, Verdichevski M., Sykes J., Jaffer S. R., Kish S. J. (2012) All-cause mortality among individuals with disorders related to the use of methamphetamine: A comparative cohort study. *Drug and Alcohol Dependence*. 125: 290-294.
32. Campollo O., Roman S., Panduro A., Hernandez G., Diaz-Barriga L., Balanzario M. C., **Cunningham J. K.** (2012) Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. *Drug and Alcohol Dependence*. 123: 269-272.
33. Callaghan R. C., **Cunningham J. K.**, Sykes J., Kish S. J. (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. *Drug and Alcohol Dependence*. 120: 35-40.
34. Callaghan R. C., **Cunningham J. K.**, Allebeck P., Arenovich T., Sajeev G., Remington G., Boileau I., Kish S. J. (2012) Methamphetamine use and schizophrenia: a population-based cohort study in California. *American Journal of Psychiatry*. 169: 389-396.
35. **Cunningham J. K.**, Bojorquez I., Campollo O., Liu L.-M., Maxwell J. C. (2011) Intervenciones dirigidas a precursores químicos de metanfetamina en México: Impacto en los ingresos a tratamiento por drogas en México y Tejas. [Interventions directed at methamphetamine precursor chemicals in Mexico: impact on drug treatment admissions in Mexico and Texas.] *Anuario de Investigación en Adicciones*. 12: 5-19.
36. Campollo O., Diaz F., Prado C. M., **Cunningham J.** (2011) Residential treatment services in west central Mexico: resources and needs. *Anuario de Investigación en Adicciones*. 12: 96-97.
37. Campollo O., Diaz F., Prado C. M., **Cunningham J.**, Avila D. S. (2011) Evaluación de clínicas de tratamiento residencial para adicciones en el estado de Jalisco. [Evaluation of residential drug treatment clinics in Jalisco.] *Anuario de Investigación en Adicciones*. 12: 97-98.

38. Campollo O., Roman S., Panduro A., Hernandez G., **Cunningham J. K.** (2011) Hepatitis B, hepatitis C y VIH en adictos a drogas y sustancias en Mexico. [Hepatitis B, hepatitis C and HIV in drug and substance addicts in Mexico.] *Anuario de Investigación en Adicciones*. 12: 98-99.
39. Verdichevski M., Burns R., **Cunningham J. K.**, Tavares J., Callaghan R. C. (2011) Trends in primary methamphetamine-related admissions to youth residential substance abuse treatment facilities in Canada, 2005-2006 and 2009-2010. *Canadian Journal of Psychiatry*. 56: 696-700.
40. **Cunningham J. K.**, Maxwell J. C., Campollo O., Cunningham K. I., Liu L.-M., Lin H.-L. (2010) Proximity to the US-Mexico border: a key to explaining geographic variation in US methamphetamine, heroin, and cocaine purity. *Addiction*. 105: 1785-1798.
41. Callaghan R. C., **Cunningham J. K.**, Sajeev G., Kish S. J. (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. *Movement Disorders*. 25: 2333-2339.
42. **Cunningham J. K.**, Bojorquez I., Campollo O., Liu L.-M., Maxwell J. C. (2010) Mexico's methamphetamine precursor chemical interventions: impacts on drug treatment admissions. *Addiction*. 105: 1973-1983.
43. Callaghan R. C., **Cunningham J. K.**, Victor J. C., Liu L.-M. (2009) Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. *Drug and Alcohol Dependence*. 105: 185-193.
44. **Cunningham J. K.**, Liu L.-M., Callaghan R. (2009) Impact of US and Canadian precursor regulation on methamphetamine purity in the United States. *Addiction*. 104: 441-453.
45. **Cunningham J. K.**, Liu L.-M. (2008) Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. *Social Science & Medicine*. 66: 1463-1473.
46. **Cunningham J. K.**, Liu L.-M., Muramoto M. (2008) Methamphetamine suppression and route of administration: precursor regulation impacts on snorting, smoking, swallowing and injecting. *Addiction*. 103: 1174-1186.
47. **Cunningham J. K.**, Liu L.-M. (2005) Impacts of federal precursor regulations on methamphetamine arrests. *Addiction*. 100: 479-488.
48. **Cunningham J. K.**, Liu L.-M. (2003) Guidelines for measuring impacts of methamphetamine precursor regulations. *Addiction*. 98: 1463-1464.
49. **Cunningham J. K.**, Liu L.-M. (2003) Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. *Addiction*. 98: 1229-1237.
50. **Cunningham J. K.**, Stoeckert J. A. (1992) Evaluations of 3M/House single channel and Nucleus multichannel cochlear implants. *The American Journal of Otology*. 13: 449-453.
51. **Cunningham J. K.** (1990) Parent's evaluations of the effects of the 3M/House cochlear implant on children. *Ear and Hearing*. 11: 375-381.

52. Fujikawa S., **Cunningham J. K.** (1989) Practices and attitudes related to hearing: A survey of executives. *Ear and Hearing*. 10: 357-360.
53. Berliner K. I., **Cunningham J. K.**, House W. F., House J. W. (1987) Effect of the cochlear implant on tinnitus in profoundly deaf patients. In Feldman H. (ed.) *Proceedings III International Tinnitus Seminar*. Munster: Harsch Verlag Karlsruhe.
54. Eisenberg L. S., Kirk K. I., Thielemeir M. A., Luxford W. M., **Cunningham J. K.** (1986) Cochlear implants in children: speech production and auditory discrimination. *The Otolaryngologic Clinics of North America*. 19: 409-421.

Selected Scholarly Presentations, Invited:

- Universidad de Guadalajara/Centro Universitario de Ciencias de la Salud/Antiguo Hospital Civil de Guadalajara. Métodos Epidemiológicos en Estudios Binacionales: Impacto Sobre la Salud del Control de Precursores de Anfetaminas en Norteamérica. [Epidemiologic Methods for Bi-national Studies: Impact of Amphetamine Precursor Control on Health in North America.] Guadalajara, Jalisco, Mexico. March 2013.
- National Institute on Drug Abuse, Community Epidemiology Work Group. Illicit Drugs and Border Issues in Arizona. Locations distributed throughout the USA. Semi-annual conferences (January and June) 2005-2013.
- The University of Texas. Trends in Clandestine Methamphetamine Laboratories, Drug Purity, and Drug Price in US States on the Mexico Border. El Paso, TX. May 2012.
- The University of Arizona, Department of Family and Community Medicine. A New Type of Methamphetamine in the USA. Tucson, Arizona. May 2012.
- The University of Arizona, Department of Family and Community Medicine. Methamphetamine and Other Illicit Drugs: Trends and Interventions. Tucson, Arizona. August 2011.
- US-Mexico Border Initiative. Impact of the US-Mexico Border on Drug Purity throughout the United States. El Paso, TX. August 2010.
- National Institute on Drug Abuse. Testing the Validity of Mexico's National Drug Treatment Admissions System (SISVEA) as an Outcome Measure for Drug Policy Analysis. Boston, MA. June 2010.
- COMEXUS. Impacts of Mexico, Canada and US Methamphetamine Precursor Chemical Policies. Mexico City, Mexico. February 2010.
- Health Canada. Impact of Methamphetamine Precursor Chemical Policy in North America. Ottawa, ON. January 2010.
- University of Toronto. Impact of Methamphetamine Precursor Chemical Policy in North America. Toronto, ON. October 2009.

Southwestern School for Behavioral Health Studies. Education on Methamphetamine and Other Illicit Drugs for Health Professionals. Tucson, AZ. August 2008.

Southwestern School for Behavioral Health Studies. Illicit Drug Trends in Arizona. Tucson, AZ. August 2008.

Arizona Governor's Office on Substance Abuse. The Function of Drug Epidemiologic Work Groups. Phoenix, AZ. September 2007.

The University of Arizona, College of Public Health. Methamphetamine Trends and Precursor Chemical Regulation. Tucson, AZ. November 2007.

Selected Scholarly Presentations, Submitted:

North American Primary Care Research Group. Does Perception Match Practice in the Care and Beliefs about Patients on Chronic Narcotics? A report from DesertNet. New Orleans, LA. December 2012.

National Hispanic Science Network on Drug Abuse. Occult Hepatitis B among In-treatment Non-injecting Drug Users (NIDUs) in West Central Mexico. San Diego, CA. September 2012.

National Hispanic Science Network on Drug Abuse. Residential Drug Treatment Clinics in Jalisco, Mexico: Staff and Service Characteristics. San Diego, CA. September 2012.

UCLA Center for Advancing Longitudinal Drug Abuse Research: Summer Institute on Longitudinal Research. Characteristics and Evolution of a Smoking Cessation Clinic in a Public Hospital in Mexico. Marina del Rey, California. August 2012.

UCLA Center for Advancing Longitudinal Drug Abuse Research: Summer Institute on Longitudinal Research. Occult Hepatitis B among In-Treatment Non-Injecting Drug Users (NIDUS) in West Central Mexico. Marina del Rey, California. August 2012.

College on Problems of Drug Dependence. Residential Drug Treatment Clinics in Jalisco, Mexico: Staff and Service Characteristics. Palm Springs, CA. June 2012.

College on Problems of Drug Dependence. Occult Hepatitis B among In-treatment Non-injecting Drug Users in West Central Mexico. Palm Springs, CA. June 2012.

Society of Teachers of Family Medicine. Practices, Attitudes, Self-Efficacy, and Perceived Barriers for Preventing and Treating Obesity in the Primary Care Clinic. Seattle, Washington. April, 2012.

National Hispanic Science Network on Drug Abuse. Regulatory Compliance of Residential Treatment Clinics in the West Central State of Jalisco, Mexico. Coral Gables, FL. August 2011.

National Hispanic Science Network on Drug Abuse. Residential Treatment Services in West Central Mexico: Resources and Needs in Jalisco. Coral Gables, FL. August 2011.

College on Problems of Drug Dependence. Regulatory Compliance of Residential Treatment Clinics in West Central Mexico. Hollywood FL. June 2011.

- College on Problems of Drug Dependence. Residential Treatment Services in West Central Mexico: Resources and Needs. Hollywood FL. June 2011.
- Semana Nacional de Gastroenterología. Hepatitis B, Hepatitis C y VIH en Adictos a Drogas y Sustancias en Mexico. [Hepatitis B, hepatitis C and HIV in drug and substance addicts in Mexico.] Acapulco, Mexico, November 2010.
- National Hispanic Science Network on Drug Abuse. Early Detection, Brief Intervention, and Addiction Prevention “CAPA-CNV” Clinics Program in Jalisco, Mexico. New Orleans, LA. October 2010.
- National Hispanic Science Network on Drug Abuse. Hepatitis B, Hepatitis C and HIV in Non-Injecting Drug Users in West Central Mexico. New Orleans, LA. October 2010.
- College on Problems of Drug Dependence. Route of administration of methamphetamine/amphetamine: How impaired are M/A swallowers? Reno, NV. June 2009.
- Society for Prevention Research. Impact of Precursor Regulation, a Methamphetamine Prevention Policy, on Drug Treatment Demand in Mexico. Washington, DC. May 2009.
- American Public Health Association. Drug Purity, Morbidity, and Violence in Arizona and Their Relation to the Mexico Border. San Diego, CA. November 2008.
- American Public Health Association. Development and Evaluation of MethOIDE (Methamphetamine and Other Illicit Drug Education): A New Program for Health Professionals. San Diego, CA. November 2008.
- Charles Drew University of Medicine and Science. 4th Annual Drug Abuse Research Symposium. The Impact of In-Custody Treatment on Recidivism: Phoenix House’s New Start Program at Theo Lacy County Jail, Orange County, California. Los Angeles, CA. September 2008.